Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials

Rynn, Moira A., Riddle, Mark A., Yeung, Paul P., Kunz, Nadia R. · 2007 · American Journal of Psychiatry

Abstract

OBJECTIVE: The authors evaluated the efficacy, safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized anxiety disorder. METHOD: Two randomized, double-blind, placebo-controlled trials were conducted at 59 sites in 2000 and 2001. Participants 6 to 17 years of age who met DSM-IV criteria for generalized anxiety disorder received a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks. The primary outcome measure was the composite score for nine delineated items from the generalized anxiety disorder section of a modified version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, and the primary efficacy variable was the baseline-to-endpoint change in this composite score. Secondary outcome measures were overall score on the nine delineated items, Pediatric Anxiety Rating Scale, Hamilton Anxiety Rating Scale, Screen for Child Anxiety Related Emotional Disorders, and the severity of illness and improvement scores from the Clinical Global Impression scale (CGI). RESULTS: The extended-release venlafaxine group showed statistically significant improvements in the primary and secondary outcome measures in study 1 and significant improvements in some secondary outcome measures but not the primary outcome measure in study 2. In a pooled analysis, the extended-release venlafaxine group showed a significantly greater mean decrease in the primary outcome measure compared with the placebo group (-17.4 versus -12.7). The response rate as indicated by a CGI improvement score <3 was significantly greater with extended-release venlafaxine than placebo (69% versus 48%). Common adverse events were asthenia, anorexia, pain, and somnolence. Statistically significant changes in height, weight, blood pressure, pulse, and cholesterol levels were observed in the extended-release venlafaxine group. CONCLUSIONS: Extended-release venlafaxine may be an effective, well-tolerated short-term treatment for pediatric generalized anxiety disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/ajp.2007.164.2.290

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 29

  1. 10.1016/S0006-3223(99)00248-6 · DOI
  2. 10.1097/00008480-199708000-00006 · DOI
  3. Costello EJ, 1995, Anxiety Disorders in Children and Adolescents, 109
  4. 10.1111/j.1600-0447.1990.tb05492.x · DOI · Paper page
  5. 10.1097/00004583-199905000-00017 · DOI · Paper page
  6. 10.1097/00004583-199907000-00008 · DOI · Paper page
  7. 10.1001/archpedi.157.1.17 · DOI · Paper page
  8. 10.1176/appi.ajp.160.4.749 · DOI · Paper page
  9. 10.1176/appi.ajp.161.9.1642 · DOI
  10. 10.1002/da.10146 · DOI · Paper page
  11. Bernstein GA, 2004, Child and Adolescent, 557
  12. 10.1089/cap.1997.7.17 · DOI
  13. 10.1097/00004583-199409000-00009 · DOI
  14. 10.1176/appi.ajp.158.12.2008 · DOI · Paper page
  15. 10.1097/01.CHI.0000037049.04952.9F · DOI · Paper page
  16. 10.1176/appi.ajp.157.6.968 · DOI · Paper page
  17. 10.1001/jama.283.23.3082 · DOI · Paper page
  18. Chaput F, 1999, Shaffer D: The Columbia KSADS (Schedule for Affective DIsorders and Schizophrenia for School Aged Children)
  19. Puig-Antich J, 1978, Chambers WJ: Schedule for Affective Disorders and Schizophrenia for School-Age Children (KIDDIE-SADS)
  20. Poznanski EO, 1985, Psychopharmacol Bull, 21, 979
  21. 10.1097/00004583-199707000-00021 · DOI · Paper page
  22. 10.1186/1471-244X-4-26 · DOI
  23. 10.1001/archpsyc.56.6.493 · DOI · Paper page
  24. 10.1111/j.1469-7610.1995.tb01300.x · DOI · Paper page
  25. Davidson JR, 2001, J Clin Psychiatry, 62, 46, 10.4088/JCP.v62n0110 · DOI
  26. 10.1097/01.chi.0000121065.29744.d3 · DOI · Paper page
  27. Grunbaum JA, 2004, MMWR Surveill Summ, 53, 1
  28. Kusiak V, 2003, Penn, Wyeth Pharmaceuticals
  29. Hammad TA, 2004, Review and Evaluation of Clinical Data

Cited by

See all 188

Metadata

Authors
Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R.
Venue
American Journal of Psychiatry
Published
2007-02
Volume
164
Issue
2
Pages
290-300
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2115556211
Cited by
188
References
8
FWCI
17.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. https://app.cochat.ai/papers/10.1176/ajp.2007.164.2.290
The paper
Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007). Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. American Journal of Psychiatry. https://doi.org/10.1176/ajp.2007.164.2.290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.